These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35508346)

  • 1. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
    Matsuoka K; Nagano K; Nagasaki S; Murata Y; Hisamatsu T
    BMJ Open; 2022 May; 12(5):e060081. PubMed ID: 35508346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Panaccione R; Danese S; Sandborn WJ; O'Brien CD; Zhou Y; Zhang H; Adedokun OJ; Tikhonov I; Targan S; Abreu MT; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Arasaradnam RP; Sands BE; Marano C
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1658-1675. PubMed ID: 33086438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
    Thunberg J; Björkqvist O; Hedin CRH; Forss A; Söderman C; Bergemalm D; ; Olén O; Hjortswang H; Strid H; Ludvigsson JF; Eriksson C; Halfvarson J
    United European Gastroenterol J; 2022 Sep; 10(7):631-639. PubMed ID: 35834389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Fumery M; Filippi J; Abitbol V; Biron A; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Nachury M; Amiot A
    Aliment Pharmacol Ther; 2021 Oct; 54(7):944-951. PubMed ID: 34296456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Feb; 101(7):e28873. PubMed ID: 35363198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy.
    Chiappetta MF; Viola A; Mastronardi M; Turchini L; Carparelli S; Orlando A; Biscaglia G; Miranda A; Guida L; Costantino G; Scaldaferri F; Bossa F; Renna S; Cappello M; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Expert Opin Biol Ther; 2021 Nov; 21(11):1483-1489. PubMed ID: 34521307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Taxonera C; Olivares D; López-García ON; Alba C
    Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.
    Dalal RS; Esckilsen S; Barnes EL; Pruce JC; Marcus J; Allegretti JR
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2399-2401.e4. PubMed ID: 33775893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
    Chaparro M; Garre A; Iborra M; Sierra-Ausín M; Barreiro-de Acosta M; Fernández-Clotet A; de Castro L; Boscá-Watts M; Casanova MJ; López-García A; Lorente R; Rodríguez C; Carbajo AY; Arroyo MT; Gutiérrez A; Hinojosa J; Martínez-Pérez T; Villoria A; Bermejo F; Busquets D; Camps B; Cañete F; Manceñido N; Monfort D; Navarro-Llavat M; Pérez-Calle JL; Ramos L; Rivero M; Angueira T; Camo Monterde P; Carpio D; García-de-la-Filia I; González-Muñoza C; Hernández L; Huguet JM; Morales VJ; Sicilia B; Vega P; Vera I; Zabana Y; Nos P; Suárez Álvarez P; Calviño-Suárez C; Ricart E; Hernández V; Mínguez M; Márquez L; Hervías Cruz D; Rubio Iturria S; Barrio J; Gargallo-Puyuelo C; Francés R; Hinojosa E; Del Moral M; Calvet X; Algaba A; Aldeguer X; Guardiola J; Mañosa M; Pajares R; Piqueras M; García-Bosch O; López Serrano P; Castro B; Lucendo AJ; Montoro M; Castro Ortiz E; Mesonero F; García-Planella E; Fuentes DA; Bort I; Delgado-Guillena P; Arias L; Iglesias A; Calvo M; Esteve M; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Nov; 15(11):1846-1851. PubMed ID: 33860795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for treating ulcerative colitis: an expert opinion.
    Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.